RecruitingNCT03603977
Simplified Treatment of Anti-retrovirus in China (C-STAR)
A Simplified Therapy Regimen Study of Lopinavir and Ritonavir Combined With Lamivudine for HIV-1 Infected Patients in the Real World of China
Sponsor
Guangzhou 8th People's Hospital
Enrollment
600 participants
Start Date
Nov 1, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
To observe the efficacy and safety of simplified therapy regimen for treating with HIV-1 infected patients in Chinese real word.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- HIV-1 infection confirmed
- Agree to use simplified therapy regimen.
- Agree to detect CD4 count at least once per half a year
Exclusion Criteria3
- Have participated in HIV vaccine clinical trial or other drug trials in the past three months.
- Patients who could not complete the scheduled follow-up (such as weakness and poor compliance).
- Patients who have the history of resistance or allergy to LPV/r or 3TC.
Interventions
DRUGLpv/r+3TC
It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03603977
Related Trials
Appalachian Partnership to Reduce Disparities (Aim 2)
NCT043784391 location
MyPEEPS LITE Trial
NCT067416312 locations
MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM
NCT067416181 location
An Integrated Intervention Using a Pill Ingestible Sensor System
NCT064805781 location
Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study
NCT072987851 location